A B S T R A C T
Background. Early prevention of diabetic nephropathy is not successful as early interventions have shown conflicting results, partly because of a lack of early and precise indicators of disease development. Urinary proteomics has shown promise in this regard and could identify those at high risk who might benefit from treatment. In this study we investigate its utility in a large type 2 diabetic cohort with normoalbuminuria. Methods. We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial. Patients were allocated to candesartan or placebo, with the aim of slowing the progression of retinopathy. The secondary endpoint was development of persistent microalbuminuria (three of four samples). We used a previously defined chronic kidney disease risk score based on proteomic measurement of 273 urinary peptides (CKD273-classifier). A Cox regression model for the progression of albuminuria was developed and evaluated with integrated discrimination improvement (IDI), continuous net reclassification index (cNRI) and receiver operating characteristic curve statistics. Results. Seven hundred and thirty-seven patients were analysed and 89 developed persistent microalbuminuria (12%) with a mean follow-up of 4.1 years. At baseline the CKD273-classifier predicted development of microalbuminuria during follow-up, independent of treatment (candesartan/placebo), age, gender, systolic blood pressure, urine albumin excretion rate, estimated glomerular filtration rate, HbA1c and diabetes duration, with hazard ratio 2.5 [95% confidence interval (CI) 1.4-4.3; P ¼ 0.002] and area under the curve 0.79 (95% CI 0.75-0.84; P < 0.0001). The CKD273-classifier improved the risk prediction (relative IDI 14%, P ¼ 0.002; cNRI 0.10, P ¼ 0.043). Conclusions. In this cohort of patients with type 2 diabetes and normoalbuminuria from a large intervention study, the CKD273-classifier was an independent predictor of microalbuminuria. This may help identify high-risk normoalbuminuric patients for preventive strategies for diabetic nephropathy.
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I N T R O D U C T I O N
It is currently estimated that more than 381 million people worldwide are affected by diabetes, and in 2035 the number will increase to more than 591 million [1] , 90% of whom will have type 2 diabetes. Approximately 35% of these patients develop diabetic nephropathy, characterized by increasing albuminuria and blood pressure, declining renal function and development of end-stage renal disease. nephropathy have an increased morbidity and mortality from cardiovascular disease.
Microalbuminuria (urinary albumin excretion 30-299 mg/ 24 h or 30-299 mg albumin/g creatinine) is an independent predictor of overt nephropathy, loss of renal function and an increase in cardiovascular disease in patients with diabetes [2] . Blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the progression from microalbuminuria to diabetic nephropathy. With the success of RAAS blockade in established microalbuminuria, trials of these agents in normoalbuminuric patients, i.e. at an earlier stage of disease, were initiated, yet results diverged, with insufficient evidence to change clinical practice [3] [4] [5] [6] [7] . Explanations for these disappointing findings include the high intra-individual variability of urinary albuminuria, and imprecision of the assay at such low levels. Yet early intervention in those at high-risk of diabetic nephropathy remains an attractive proposition, and what are needed are better biomarkers or risk indicators. Several risk factors such as hypertension, hyperglycaemia, smoking, retinopathy and elevated urinary albumin excretion within the normal range have been identified but are not sufficient to identify all those who progress [8] . In addition, a new meta-analysis points at the benefit of RAAS blockade in normoalbuminuric type 2 diabetic patients [9] . Therefore, there is a need to identify patients at high risk for nephropathy, so that intervention can be better targeted.
Urinary proteomics has attracted significant attention in the last decade due to its capacity to identify small proteins and peptides associated with pathophysiological changes, particularly at an early stage of disease [10] . A specific pattern of 273 protein fragments (CKD273-classifier) differently expressed in the urine from patients with chronic kidney disease compared with healthy controls has been developed to discern those with chronic kidney disease [11] . The CKD273-classifier has been shown to identify normoalbuminuric patients with type 1 diabetes who progress to macroalbuminuria [12] . Moreover, in a case-control study of type 2 diabetic patients with normo-or microalbuminuria the classifier was associated with progression [13] . However, these previous studies were too small to be definitive, and longitudinal validation in larger wellcharacterized populations is needed.
In this study we set out to confirm the ability of the urinary proteomic-based CKD273-classifier, using a previously established cut-off to define high-risk patients, to predict the development of microalbuminuria in a large cohort of normoalbuminuric patients with type 2 diabetes. The patients had been followed as part of a randomized, placebocontrolled, double-masked trial of the angiotensin receptor blocker candesartan for the prevention of progression of retinopathy, the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study) [14] . In this respect, we also analysed the response of treatment (candesartan/placebo) given risk classification. In addition, we compared the predictive power of the CKD273-classifier to established clinical progression promoters. Our hypothesis was that the CKD273-classifier would be able to predict early chronic kidney disease and provide added value to established conventional clinical risk factors.
M A T E R I A L S A N D M E T H O D S

Setting and participants
A post hoc analysis was performed of the clinical trial DIRECT-Protect 2. The design of the study is described elsewhere [14] . In brief, the study investigated the effect of candesartan on the progression of mild or moderate retinopathy in 1905 type 2 diabetic patients (age: 37-75 years; diabetes duration: 1-20 years) who were normoalbuminuric, and were either normotensive or had well-controlled hypertension (defined as blood pressure 160/90 mmHg) with non-RAAS-blocker therapy at baseline. The patients were randomized to candesartan 16 mg/day increasing to 32 mg/day after 1 month or matching placebo in a double blinded design, with a mean treatment period of 4.7 years. Randomization was stratified by hypertensive status, 62% of the patients were treated at baseline with antihypertensive agents other than angiotensin-converting enzyme inhibitor (ACEi) or angiotensinogen receptor blocker, 5% had previously had a myocardial infarction and 2% had previously experienced stroke.
Patients were seen every 6 months. Routine serum biochemistry, total and high-density lipoprotein (HDL) cholesterol, and glycated haemoglobin A 1c (HbA 1c ; aligned to DCCT standards) were measured in a central laboratory. Blood pressure was measured seated after 5 min rest using an automated device (Omron M4, Omron Healthcare Company, Kyoto, Japan) with an appropriate-sized cuff. Of three readings, the mean of the last two was used in the analysis. Patients who were or became hypertensive (blood pressure >140/85 mmHg) but whose urine albumin excretion rate (UAER) remained normal could be prescribed any non-RAAS-blocking antihypertensive agent according to international and national clinical guidelines. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula [15] .
Definition of endpoints
Descriptions of the endpoints are described elsewhere [14] . In brief, the UAER was measured in two times overnight urine samples using nephelometry (Beckmann Array, Beckmann Instruments, High Wycombe, UK) at baseline and annually thereafter. The lower limit of detection of albumin concentration was 20 mg/L, with a maximum allowable coefficient of variation of 5% in the mean range of 50-100 mg/L. If the rate was >20 mg/min in any of the samples, two additional samples were collected within a 3-month period, and if three or four of these four consecutive samples were positive, the participant was classified as having reached a microalbuminuria event and openlabel ACEi therapy was allowed. Overall randomization to candesartan treatment had no effect on the development of renal endpoints as previously published [6] ; therefore, data were analysed without stratification by treatment allocation.
Sample selection
Urine samples from the baseline visit were used in the present study for capillary electrophoresis-mass spectrometry (CE-MS) analysis. In the DIRECT-Protect 2 study a total of 309 study sites in 30 countries participated. Samples from baseline U r i n a r y p r o t e o m i c s i n t y p e 2 d i a b e t i c p a t i e n t s
were only stored in approximately half of the sites. Thus from 1905 patients in DIRECT-Protect 2, urine samples were available for analysis from 817 patients. Twenty-four samples failed quality control for the proteomics score. In addition 56 subjects were excluded from the statistical analyses because there was no information of the UAER after randomization (n ¼ 32) and/or the event of microalbuminuria was present at the time of randomization (n ¼ 25). Seven hundred and thirty-seven subjects were included in the statistical analysis ( Figure 1 ). Subjects included in the analysis were more likely to be male (54 versus 48% male, P ¼ 0.012) and older (57.5 versus 56.5 years, P ¼ 0.005), more likely to have a lower UAER (6.2 versus 7.8 lg/ min, P < 0.0001), higher total cholesterol (5.4 versus 5.2 mmol/ L), higher HDL cholesterol (1.44 versus 1.37, P < 0.0001) and lower eGFR (69 versus 71 mL/min/1.73 m 2 , P ¼ 0.29), and were more likely to use antihypertensive treatment (66 versus 60%, P ¼ 0.006) in comparison with subjects excluded from the analysis (Supplementary data, Table S5 ).
Preparation of samples and CE-MS analysis
Urine samples were kept at À80
C from the time of collection to preparation. A 0.7 mL aliquot was thawed immediately before use, diluted with 0.7 mL urea (2 mol/L) and NH 4 OH (10 mmol/L) containing 0.02% sodium dodecyl sulphate and filtered using Centrisart ultracentrifugation filter devices (20 kDa molecular mass cut-off; Sartorius, Goettingen, Germany) at 3000 g until 1.1 mL of filtrate was obtained. This was desalted using a PD-10 column (GE Healthcare, Stockholm, Sweden) equilibrated with 0.01% NH 4 OH in HPLC-grade water. Finally, samples were lyophilized and resuspended in HPLC-grade water to a final protein concentration of 0.8 lg/lL, checked by BCA assay (Interchim, Montlucon, France). CE-MS analysis was performed as previously described [16] . The limit of detection was $1 fmol, with mass resolution above 8000, enabling resolution of monoisotopic mass signals for z 6. After charge deconvolution, mass deviation was <25 ppm for monoisotopic resolution and <100 ppm for unresolved peaks (z > 6). Details on analytical precision were reported recently [17] .
Data processing
Overall methodology was as previously described by Roscioni et al. [13] . A minimum of 950 peptides/proteins had to be detected with a minimal MS resolution of 8000 in a minimal migration time interval of 10 min. Mass-spectral ion peaks representing identical molecules at different charge states were deconvoluted into single masses using MosaiquesVisu software as described [2, 18] . Reference signals of 1770 urinary polypeptides were used for CE-time calibration by linear regression. For normalization of analytical and urine dilution variances, linear regression was performed based on the data of 29 'housekeeping' peptides generally present in urine samples with small relative standard deviation (SD) [19] . All detected peptides were deposited, matched and annotated in a Microsoft SQL database.
CKD273-classifier
The datasets were examined with respect to scoring of the CKD273-classifier. This support vector machine-driven classifier combines the data on 273 distinct urinary peptides, found to be significantly altered in chronic kidney disease, to give a continuous numeric variable that represents the probability of disease being present [11] . CE-MS analysis was performed blinded on all samples. The data were evaluated using the CKD273-classifier. Subsequently, the data were unblinded. Based on previous studies and an ongoing clinical trial [20] , we used the CKD273-classifier. As for previous studies, a score of >0.343 identifies high-risk subjects. Subjects below the cut-off are identified as low risk [11] . As an exploratory aim we investigated the impact of adjusting the cut-point (0.154) in order to define 20% of the population as high risk.
Ethics
The DIRECT-Protect 2 study was conducted in accordance with Declaration of Helsinki and GCP/ICH. The study was approved by each participating centre's regional ethical committee, the national competent authority, and all patients gave their written informed consent prior to any study procedures. 
After data lock, all study data and collected biological material were anonymized.
Statistics
Cox regression analysis was performed both in unadjusted and adjusted models. For the backward selection model the level of significance was set to 0.05. Integrated discrimination improvement (IDI) calculation was based on Cox regression models. Predictive values for receiver operating characteristic (ROC) curves and continuous net reclassification index (cNRI) were based on logistic models with a class shift level set at 0.05 for movement both up and down in both cases and controls [21] . Covariates other than categorical variables are adjusted to standard deviation (z scores) when used in the models. P-values <0.05 were deemed significant. SAS Enterprise Guide version 5.1 by SAS Institute, Inc., Cary, NC, USA was used for statistical analysis.
R E S U L T S
Of 737 subjects from the DIRECT-Protect 2 study with normoalbuminuria at the time of randomization, 89 (12%) developed the endpoint of persistent microalbuminuria during follow-up. Baseline characteristics are displayed in Table 1 . The characteristics differed between subjects who experienced the event during follow-up compared with non-progressors: they were more likely to be male and they had a significantly higher systolic blood pressure, weight, waist-to-hip ratio and UAER. HDL cholesterol was significantly lower in the event group and the eGFR was slightly higher.
In
Based on the previously defined cut-off for the CKD273-classifier, 72 (9.8%) patients were identified as high risk for development of chronic kidney disease, and the remainder as low-risk patients (Table 1) . The negative predictive value of the CKD273-classifier was 89.3%.
The event proportion was 25.0% in the group identified as high risk and 10.7% in the low-risk group (P ¼ 0.0004). We found that the patients with a high-risk CKD273-classifier pattern had a significantly higher event rate of persistent microalbuminuria when compared with the low-risk pattern, shown in Figure 2 . The incidence rate of persistent microalbuminuria for the high-risk group was 6, 10, 5, 5 and 3% for years 1-5, respectively, and 1, 4, 3, 3 and 1% for the low-risk group. In an unadjusted Cox model, the high-risk patients had a 2.6-fold increased risk of development of microalbuminuria during 4.1 years of follow-up [hazard ratio (HR) 2.6; 95% confidence interval (CI) 1.6-4.4; P ¼ 0.0002] ( Table 2 ). In a backward selection model age, UAER, HDL cholesterol and eGFR as well as the CKD273-classifier were independent predictors of persistent microalbuminuria (data given in Table 3 ). In a fully adjusted Cox model with baseline age, gender, systolic blood pressure, HbA 1c , UAER, weight, HDL cholesterol, eGFR, antihypertensive treatment and smoking status, the CKD273-classifier remained an independent predictor with an HR of 2.5 (95% CI 1.4-4.4; P ¼ 0.0013; Table 2 ).
The additive effect of the CKD273-classifier on risk prediction was evaluated with the use of IDI. The comparison is based on two adjusted Cox models, both including baseline age, UAER, HDL cholesterol and eGFR with and without the . In a more crude comparison, only adjusting for the UAER, the performance of the CKD273-classifier gave an IDI of 0.108 (P ¼ 0.008) with an rIDI of 14.2% (Table 4) . Adding the CKD273-classifier significantly improved performance for risk prediction evaluated with cNRI in a crude model as well as in a model adjusted for the independent predictors UAER, eGFR, HDL cholesterol and age, but not in a fully adjusted model. In addition, the performance and additive predictive value were also evaluated with ROC curves using a logistic model. Including age, UAER, HDL cholesterol and eGFR gave an area under the curve (AUC) of 0.78, while adding the CKD273-classifier resulted in an AUC of 0.79 (P ¼ 0.48 for difference; Table 4 ).
Using the alternative 20% cut-point for the proteomics classifier, the predictive performance remained significant with HR 1.74 (95% CI 1.10-2.77; P ¼ 0.019; adjusted models shown in Supplementary data).
Similar to the original study, treatment with candesartan had no significant effect on occurrence of the event of persistent microalbuminuria in this subpopulation (P ¼ 0.89) [5] . Average time to event did not differ between candesartantreated (2.4 years, SD 1.3) and placebo-treated patients (2.0 years, 1.0; P ¼ 0.11). Stratification of the study population with the CKD273-classifier did not alter the event rates between patients treated with candesartan or placebo [high risk and candesartan: 24%, high risk and placebo: 26% (P ¼ 0.89); low risk and candesartan: 11%, low risk and placebo: 10% (P ¼ 0.68)].
D I S C U S S I O N
We have shown that the CKD273-classifier, based on urinary proteomic analysis, was able to predict early onset of diabetic kidney disease defined as progression from normoalbuminuria to persistent microalbuminuria independent of the urinary albumin excretion rate and the eGFR in a large cohort of type 2 diabetic patients. Previous studies in diabetic nephropathy that have demonstrated the discriminatory ability of the CKD273- CKD273-classifier is treated as a categorical variable (high-versus low-risk). Gender and the following baseline variables did not meet the significance level of <0.05 to remain in the model: smoking status, diabetes duration, antihypertensive treatment, weight, waistto-hip ratio, body mass index, diastolic blood pressure, systolic blood pressure, total cholesterol and HbA 1c .
classifier have either been cross-sectional [22] , small longitudinal case-control studies [12] or chronic kidney disease in general [18] . This is the first longitudinal assessment of the classifier in a large cohort of type 2 diabetic patients, with more than 4 years of follow-up, albeit as a post hoc analysis, of >700 patients from the DIRECT-Protect 2 study. Our study supports the use of the proteomic classifier as a tool to early identify type 2 diabetes patients at high risk for diabetic nephropathy. Currently, the onset of microalbuminuria is used to indicate clinical onset of nephropathy. Clinical trials have demonstrated the benefit of multifactorial intervention in type 2 diabetes patients with microalbuminuria, reducing renal and cardiovascular morbidity and mortality [23] . It is possible that additional biomarkers in blood or urine would allow even earlier identification of high-risk individuals who might benefit from intervention during normoalbuminuria. Furthermore, new markers should have the ability to predict death and end-stage renal disease [24, 25] .
Urinary proteomics is a novel method that allows hypothesis-free biomarker discovery through assessment of the urinary proteome. In contrast to blood, the urinary proteome is very stable [11] . From discovery studies comparing the urinary proteome in patients with or without chronic kidney disease, changes in 273 peptides or peptide fragments were found to differentiate cases from controls, and they were combined to form the CKD273-classifier [26] . Reduction in the number of peptides in the classifier was shown to decrease sensitivity and specificity [27] .
Subsequent longitudinal studies comparing cases with progression of albuminuria with controls with stable albumin excretion showed that the CKD273-classifier could separate cases from controls, and the effect was additive to eGFR and albuminuria [12, 13] . However, the studies were small and the ratio of cases to controls did not reflect a clinically relevant population. Therefore, a longitudinal study of a large cohort of normoalbuminuric patients not selected with regard to progression status was needed to test the utility of the classifier.
Originally, the DIRECT-Protect 2 study was designed to evaluate early intervention using candesartan as a way to slow progression of retinopathy (primary outcome) and development of microalbuminuria (secondary outcome) in patients with type 2 diabetes who were either normotensive or who had well-controlled hypertension. Candesartan did not prevent retinopathy and did not prevent the development of microalbuminuria [3, 28] . Four other studies investigating the effect of RAAS blockade on the development of microalbuminuria did show benefit [4] [5] [6] [7] , but patients in those studies were predominantly hypertensive, increasing their general risk of chronic kidney disease, and in at least one study there was an increase in adverse cardiovascular events [5] . While we demonstrated that the CKD273-classifier could identify patients with a high-risk for renal progression, treatment with candesartan did not reduce the risk significantly in these patients, as was seen in the original analysis of the total study population [3] . The potential for improved early renal risk prediction would hold promise for improved care of diabetes patients. If it qualified as an early marker, the CKD273-classifier may provide a new tool for selecting high-risk patients for focused early intervention in order to reduce the risk of adverse renal outcomes. In addition, adding the CKD273-classifier identified individuals with a low risk of developing diabetic nephropathy evidenced by the negative predictive value of 89%. This may enable identifying of subjects with no need for pharmacological treatment, thus saving them cost and from the risk of side effects.
The onset of microalbuminuria is known to be associated with other risk markers [29] . This is also the case in our study, where the level of UAER, HDL cholesterol, eGFR and age are independent predictors of persistent microalbuminuria. Therefore, the added value of any new biomarker or classifier on top of these established risk markers must be evaluated. The added value of the proteomic classifier displayed as rIDI showed a significant improvement of 8.3% in the fully adjusted model and 14.4% in the less adjusted model. In evaluation with cNRI, the reclassification was limited although significant in an adjusted model. However, the AUC from the ROC curve in a fully adjusted model was 0.79 and did not change significantly when the proteomics classifier was added. The lack of apparent added value based on both cNRI and ROC-curve results can partly be explained by the statistical model, as neither cNRI nor ROC curves include time to event. In contrast, time to event, which is different between high-and low-risk patients, is included in IDI and rIDI and thus they may be more appropriate measures of added value. Furthermore, the area under the ROC curve was already as high as 0.78 with the baseline parameters and thus there was less potential for improvement.
In our study, we were able to identify patients with the highest risk for progression to microalbuminuria and, in a clinical setting, this subgroup would be the target for an intervention. Even though the proteomic classifier is an independent predictor of the endpoint with an HR of 2.6, and is shown to add predictive value, the majority of events were in the low-risk stratum. Overlooking the majority of events is a challenge for the clinical use of the CKD273-classifier. We identified $10% of the study population as high-risk patients with the current cut-off based upon the original case-control studies. In the case-control study of type 2 patients developing micro-or macroalbuminuria by Roscioni et al., the CKD273-classifier was significant when used as a continuous variable [13] . Urinary proteomics represents a new approach to risk prediction in type 2 diabetes. The technique also offers an opportunity for better understanding of renal pathophysiology [26] . Although all the included peptides and fragments have been identified, the precise pathophysiology reflected by the complex peptide pattern making up the proteomics score remains elusive and is under continuing investigation in several different settings and cohorts [30] . From the risk score composition, it is apparent that changes in extracellular matrix components including collagen fragments (e.g. type I and III collagen a-1), and tubular proteins (e.g. uromodulin) and glycoproteins are an early feature [11, 13] . Clearly, to determine whether these findings have clinical significance, prospective studies with patient-related outcomes are needed. At present, the predictive power of the CKD273-classifier is under prospective evaluation in the EU-funded randomized trial PRIORITY, an investigator-initiated multicentre trial that will determine whether urinary proteomics can select patients at risk of developing microalbuminuria among uncomplicated normoalbuminuric patients with type 2 diabetes. In addition, the patients with a high-risk proteomics pattern will be randomized to double-masked treatment with spironolactone 25 mg once daily or placebo for 3 years, in order to assess its effectiveness as an early preventative intervention [20] . In our study the cut-point of the proteomics classifier used in the ongoing PRIORITY trial showed significant predictive performance.
Although initial findings have shown promise, further strengthened by the present data from a large randomized clinical trial in type 2 diabetes, the time for clinical introduction of urinary proteomics may be some time ahead [31] . However, the ongoing prospective studies and further exploration of the large amount of information in urinary proteomic data will certainly provide a platform for thorough evaluation of the future clinical utility of the technique.
Our study has the limitation of being a post hoc analysis from a randomized controlled trial designed with a different aim and results should be interpreted with caution. However, the cohort resembles a typical cohort of normotensive normoalbuminuric type 2 patients and the original intervention in the study did not influence the outcome. Judgement regarding the use of urinary proteomics in renal risk prediction will need results from ongoing prospective studies as described above, as well as confirming observations from other populations.
C O N C L U S I O N
In this study of patients with type 2 diabetes and normoalbuminuria from a large intervention trial, the CKD273-classifier was an independent predictor of microalbuminuria. This may provide a better opportunity to select normoalbuminuric patients at a high-risk of nephropathy for the testing of interventions for the early prevention of diabetic nephropathy.
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